Use of the Bethesda system for the cytologic diagnosis of thyroid nodules
Keywords:
thyroid nodule, fine needle biopsy, Bethesda system.Abstract
Introduction: The thyroid nodule is a common finding nowadays and, for its echographic characteristics, it constitutes a lesion different to the glandular parenchyma, with a high prevalence in the general population.
Objective: To describe the use of the Bethesda system as diagnostic method of thyroid nodules and the degree of malignancy.
Methods: A descriptive and retrospective study of 1 771 patients with diagnosis of thyroid nodule was carried out, who underwent fine needle aspiration cytology, in the Pathology Department of Dr. Juan Bruno Zayas Alfonso Teaching General Hospital in Santiago de Cuba during 2016-2019.
Results: In the series there was a prevalence of the 41-50 age group and the mean age was of 49,51±13,14 years. Also, the category II of the Bethesda system was notable (73.8 %); as long as, of the 204 diagnosed corresponding to the category III, 111 were surgically intervened and 29 of them presented mlignancy (27.6 %). The degree of malignancy oscillated between 22.8 and 36.0 %.
Conclusions: The application of the Bethesda system was very useful for the cytopathologic diagnosis of thyroid nodules and the degree of malignancy corresponded with appropriate figures.Downloads
References
2. Kraus Fischer G, Alvarado Bachmann R, de Rienzo Madero B, Núñez García E, Vega de la Peña M de la, Zerrweck López C. Correlación entre el sistema Bethesda de nódulos tiroideos y el diagnóstico histopatológico pos tiroidectomía. Rev Med Inst Mex Seguro Soc. 2020 [citado 16/08/2022];58(2):114-21. Disponible en: https://www.redalyc.org/journal/4577/457767703008/html/
3. Pinto Blázquez J, Ûrsua Sarmiento I. Anatomía Patológica de la patología de tiroides y paratiroides. Sistema Bethesda del diagnóstico citológico de la patología de tiroides. Rev ORL. 2020 [citado 16/08/2022];11(3):259-64. Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S2444-79862020000300003
4. Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology. 10 ed. Philadelphia: Elsevier Health Sciences; 2017.
5. Jiménez Guzmán HA. Asociación del tamaño tumoral e invasión extra capsular con la recurrencia cervical ganglionar en pacientes con cáncer papilar de tiroides T1-T2 N0, sometidos a tiroidectomía total [tesis]. Veracruz: Universidad Veracruzana; 2021 [citado 13/08/2022]. Disponible en: https://cdigital.uv.mx/handle/1944/50486
6. República de Cuba. Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2020. La Habana: MINSAP; 2021 [citado 16/08/2022]. Disponible en: https://files.sld.cu/bvscuba/files/2021/08/Anuario-Estadistico-Espa%c3%b1ol-2020-Definitivo.pdf
7. Puerto Lorenzo JA, Torres Ajá L, Cabanes Rojas E. Comportamiento de la enfermedad nodular tiroidea en la provincia de Cienfuegos. Rev Cuba Cir. 2021 [citado 16/08/2022];60(4). Disponible en: https://revcirugia.sld.cu/index.php/cir/article/view/1174/655
8. Guarneri C, Parada U, Fernández L, Taruselli R, Cazabán L. Rendimiento del sistema Bethesda en el diagnóstico citopatológico del nódulo tiroideo en un centro universitario (Hospital de Clínicas) de Uruguay, diez años de experiencia. Rev Méd Urug. 2022 [citado 16/08/2022];38(2):e38208. Disponible en: http://www.scielo.edu.uy/pdf/rmu/v38n2/1688-0390-rmu-38-02-e207.pdf
9 Mitsui Nakane NK, Sanabria Báez G. Efectividad de la PAAF bajo guía ecográfica con la biopsia definitiva en los pacientes portadores de patología tiroidea, año 2016 - 2018. Rev Inst Med Trop. 2021 [citado 26/11/2022];16(2)37-44. Disponible en: https://doi.org/10.18004/imt/2021.16.2.37
10. Fernández Morocho JE, García Rivera ME, Álvarez Orellana PB, Gordón Reyes KL, Jadan Sumba NA. Validación de la punción aspiración con aguja fina guiada por ecografía en el diagnóstico de cáncer de tiroides. Anatomía Digital 2022 [citado 16/08/2022];5(3.1):6-25. Disponible en: https://doi.org/10.33262/anatomiadigital.v5i3.1.2234
11. Arias Leal ML. Nódulo tiroideo: un enfoque integral. Rev Médica Sinergia. 2022 [citado 16/08/2022];7(5):e803. Disponible en https://revistamedicasinergia.com/index.php/rms/article/view/803
12. Mosca L, Ferraz da Silva LF, Campos Carneiro P, Azevedo Chacón D, Furtado de Araujo-Neto VJ, Furtado de Araujo-Filho VJ, et al. Malignancy rates for Bethesda III subcategories in thyroid fine needle aspiration biopsy (FNAB). Clínics (Sao Paulo). 2018 [citado 16/08/2022];73:e370. Disponible en: https://doi.org/10.6061/clinics/2018/e370
13. Mora Guzmán I, Muñoz de Nova JL, Marín Campos C, Jiménez Heffernan JA, Cuesta Pérez JJ, Lahera Vargas M, et al. Rendimiento del sistema Bethesda en el diagnóstico citopatológico del nódulo tiroideo. Cir Esp. 2018 [citado 06/05/2022];96(6):363-8. Disponible en: https://www.elsevier.es/es-revista-cirugia-espanola-36-articulo-rendimiento-del-sistema-bethesda-el-S0009739X18301957
14. Al-Kurd A, Maree A, Mizrahi I, Kaganov K, Weinberger JM, Mali B, et al. An Institutional Analysis of Malignancy Rate in Bethesda III and IV Nodules of the Thyroid. Am J Otolaryngol Head Neck Surg. 2019 [citado 06/05/2022];2(1):1034. Disponible en: http://www.remedypublications.com/american-journal-of-otolaryngology-and-head-and-neck-surgery-abstract.php?aid=352
15. García Pascual L, Lluisa Suralles M, Morlius X, García Cano L, González Minguez C. Prevalencia y malignidad asociada de las citologías de categoría Bethesda III de nódulos tiroideos según el grupo “atipia citológica” o “atipia arquitectónica”. Endocrinol Diabetes Nutr. 2018 [citado 06/05/2022];65(10):577-83. Disponible en: https://www.elsevier.es/es-revista-endocrinologia-diabetes-nutricion-13-pdf-S2530016418301794
16. Reuter KB, Mamone M, Ikejiri ES, Camacho CP, Nakabashi C, Janovsky C et al. Bethesda Classification and Cytohistological Correlation of Thyroid Nodules in a Brazilian Thyroid Disease Center. Eur Thyroid J. 2018 [citado 06/08/2022];7(3):133-8. Disponible en: https://etj.bioscientifica.com/view/journals/etj/7/3/ETJ488104.xml
Published
How to Cite
Issue
Section
License
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
![Secimed](/templates/images/secimed.png"){kind=small}
Guidelines for authors
